Yang X, Gu X, Pei X, Zhu L
Department of Hematology, Beijing Hospital.
Zhonghua Xue Ye Xue Za Zhi. 1997 Jul;18(7):354-7.
To investigate the role of recombinant human hematopoietic growth factors (HGFs) in the treatment of myelodysplastic syndromes (MDS) patients.
CD34+ cells from 16 MDS patients were purified up to 96% approximately 99% by means of a immunomagnetic beads sorting system. The effects of individual and combination of HGFs on the proliferation and differentiation of the CD34+ cells were studied in semi -solid cultures.
CD34+ cells were impaired and none of the individual HGF (GM-CSF, IL-3, SCF) could effectively support their proliferation and differentiation. rh-SCF combined with GM-CSF, IL-3 or Epo could partly increase the colony forming capacity of MDS hematopoietic progenitor, however, an increase of undifferentiated blast cells colonies occurred in some high-risk MDS patients at the same time.
Proper combination of HGFs was essential for improving hematopoiesis in MDS patients.
探讨重组人造血生长因子(HGFs)在治疗骨髓增生异常综合征(MDS)患者中的作用。
借助免疫磁珠分选系统,将16例MDS患者的CD34+细胞纯化至约96%,接近99%。在半固体培养中研究HGFs单独及联合应用对CD34+细胞增殖和分化的影响。
CD34+细胞功能受损,单一HGF(粒细胞-巨噬细胞集落刺激因子、白细胞介素-3、干细胞因子)均不能有效支持其增殖和分化。重组人干细胞因子联合粒细胞-巨噬细胞集落刺激因子、白细胞介素-3或促红细胞生成素可部分提高MDS造血祖细胞的集落形成能力,但同时一些高危MDS患者未分化原始细胞集落增加。
HGFs的合理联合应用对改善MDS患者的造血功能至关重要。